EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 602 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Answers to Your Questions About the COVID-19 Vaccine March 4, 2021 Many Patients with NSCLC Show Targetable Alterations in the PI3K Pathway March 24, 2021 Woman Creates Non-Toxic Nail Polish Brand After Her Mom’s Breast Cancer... November 20, 2020 How to Tell If Cancer Information on Social Media Is “Fake... September 29, 2020 Load more HOT NEWS Dwayne Johnson Sends Special “Moana” Message To 3-Yr-Old Battling Cancer. Helping Dogs—and Humans—with Cancer: NCI’s Comparative Oncology Studies Air Pollution and Breast Cancer Risk – A Link That Calls... The National Parks Service Still Hasn’t Fixed It’s Sexual Harassment Problem
